Rhone-Poulenc may team up with Hoechst
Article Abstract:
Hoechst AG of Germany and France-based Rhone-Poulenc SA are speculated to be negotiating for possible strategic alliances and probably a full merger. Although the two companies declined to comment, the news of a possible team-up resulted in the upsurge of the two companies' shares. Both companies have implemented major changes to concentrate on life-sciences, pharmaceuticals and agrochemicals, but have not been able to match such industry players as Glaxo, Merck & Co. or Novartis AG in terms of profitability. Analysts have suggested a merger of Hoechst and Rhone-Poulenc to form the world leader in pharmaceuticals and agrochemicals.
Comment:
Is speculated to be negotiating with Hoechst AG for possible strategic alliances & probably a full merger
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
British Biotech signals a shift in its strategies
Article Abstract:
British Biotech PLC has launched a new marketing strategy and a cost-cutting move. The company will also be announcing its retirement plans for CEO Keith McCullagh. The moves were unveiled as part of the circular sent by the board to the company's shareholders, in response to charges made by Dr. Andrew Millar, a senior research executive who was terminated in April 1998. The company has also disclosed its plans to save money during the the three to four years it needs to complete the clinical testing of marimastat, an anti-cancer medicine. The company is also in discussions with potential US marketing partners for marimastat.
Comment:
Has launched a new marketing strategy and a cost-cutting move
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Bayer reconsiders independent stance
Article Abstract:
Bayer AG of Germany is considering the formation of partnerships with other firms in the pharmaceuticals business, a move that marks the firm's second thought regarding its status as an independent drug manufacturer. Bayer is expected by analysts in the pharmaceuticals business to possibly forge alliances with potential partners such as the US' DuPont Co., London, UK's Zeneca Group PLC and Sweden's Astra AB. Bayer's drug-division head, Horst Meyer, projected that the company's search for partner firms will go beyond the pharmaceuticals business.
Comment:
Is considering the formation of partnerships with other firms in the pharmaceuticals business
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: G-networks with multiple classes of signals and positive customers. On G-networks and resource allocation in multimedia systems
- Abstracts: Phnom Penh hotels battle decline in occupancy despite big changes. Savimex wants to go global
- Abstracts: Phone companies beckon Mannesmann. Germans and Italians sign a deal to create a new phone giant
- Abstracts: Fortis implies it may meet ABN Amro's Generale bid. Court lifts injunction on KBC merger. AMMB to talk with Fortis on stake sale
- Abstracts: Coupon industry takes it in-store. Gas retailers try corner store niche